• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.01%

    More On GLPGF

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials

    • Income Statement
    • Balance Sheet
    • Cash Flow

    Galapagos NV (GLPGF)

    -Other OTC
    59.80 Up 3.65(6.50%) Jul 31, 9:33AM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Galapagos NV
    Industriepark Mechelen Noord
    Generaal De Wittelaan L11 A3
    Mechelen, 2800
    Belgium - Map
    Phone: 32 1 534 29 00
    Fax: 32 1 534 29 01
    Website: http://www.glpg.com

    Details 
    Index Membership:N/A
    Sector:N/A
    Industry:N/A
    Full Time Employees:417

    Business Summary 

    Galapagos NV, a clinical stage biotech company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. Its products include GLPG0634, an orally-available selective inhibitor of Janus kinase 1, which is in Phase II clinical study for the treatment of rheumatoid arthritis and other inflammatory diseases; and GLPG1205/GLPG1690 that is in Phase IIA clinical study for treating inflammatory bowel disease, as well as in Phase II proof-of-concept study for the treatment of ulcerative colitis patients. The company is also developing MOR106, an antibody, which is in preclinical development stage for the treatment of inflammatory diseases; GSK2586184, an investigational compound that is in Phase II clinical study for the treatment of chronic immuno-inflammatory diseases consisting of SLE, psoriasis, and ulcerative colitis; and GLPG0974, an orally available small molecule, which is in Phase II clinical study to prevent free fatty acid-induced activation and migration of neutrophils towards an inflammatory site, such as in the gut of patients with inflammatory bowel disease. It has strategic alliances with GlaxoSmithKline, MorphoSys, Servier, and AbbVie to discover and develop small molecules for the treatment of inflammation, inflammatory diseases, osteoarthritis, oncology, rheumatoid arthritis/crohnÂ’s disease, and cystic fibrosis diseases. The company was founded in 1999 and is headquartered in Mechelen, Belgium.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Galapagos NV

    Key Executives 
     PayExercised
    Mr. Onno van de Stolpe , 55
    Co-Founder, Chief Exec. Officer, Managing Director and Exec. Director
    858.00KN/A
    Mr. Bart Filius MBA, 44
    Chief Financial Officer
    N/AN/A
    Dr. Piet Wigerinck Ph.D., 50
    Chief Scientific Officer
    N/AN/A
    Ms. Elizabeth Goodwin ,
    Head of Corp. Communications & Investor Relations
    N/AN/A
    Dr. Andre Hoekema Ph.D., 57
    Sr. VP of Corp. Devel.
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.